ALT241227C15500
- 0.00
- 0.000.00%
Altimmune Newsroom
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)
Altimmune Call Volume Above Normal and Directionally Bullish
Express News | Shares of Viking Therapeutics up 9.3%, Structure Therapeutics up 3.4%, Altimmune up 1.7% Premarket
Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Hims & Hers Shares Tumble as FDA Resolves Obesity Drug Shortage
Express News | Altimmune Added to Nasdaq Biotechnology Index
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Altimmune Shares Surge on CEO's CNBC Appearance
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Altimmune Stock Up More Than 25% in a Month: Here's Why
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Altimmune to Participate at Two Upcoming Investor Conferences
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Trump Nominates Marty Makary For FDA Commissioner
Executive Reshuffles: TWO, CYBR, PFG and ALT
Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024